Coating agent for inducing differentiation of pluripotent stem cells into brain capillary endothelial-like cells and its use

By using laminin 221 fragment and N-terminal vitronectin coating agent, the problems of poor reproducibility and change in differentiation efficiency in the induction of pluripotent stem cells were solved, and pluripotent stem cells to brain capillary endothelial cells were realized stable differentiation and efficient supply.

CN115175986BActive Publication Date: 2024-11-08NAGOYA CITY UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202180013715.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-02-10
Filing Date
2021-02-09
Publication Date
2024-11-08
Estimated Expiration
2041-02-09

AI Technical Summary

Technical Problem

In the prior art, when using matrix gel as a pluripotent stem cell differentiation to brain capillary endothelioid cells, there are problems of poor reproducibility and changes in differentiation efficiency, and the differentiation results of matrix gel manufacturing companies and batches will affect the differentiation results.

Method used

A coating agent containing a laminin 221 fragment and N-terminal vitronectin is used to inhibit the reduction of reproducibility and changes in differentiation efficiency during differentiation by the coating agent, providing a stable differentiation induction method.

Benefits of technology

The stable differentiation of pluripotent stem cells to cerebral capillary endothelioid cells is achieved, which improves the differentiation efficiency and reduces the cost and operational complexity in the differentiation process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115175986B_ABST
    Figure CN115175986B_ABST
Patent Text Reader

Abstract

The present invention provides a technology capable of stably supplying brain capillary endothelial-like cells. A coating agent for inducing differentiation of pluripotent stem cells into brain capillary endothelial-like cells comprises at least one of a laminin 221 fragment and an N-terminal vitronectin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a coating agent for inducing differentiation from pluripotent stem cells to brain capillary endothelial-like cells. This application is based on Japanese application No. 2020-021031 filed on February 10, 2020, and the contents described therein are incorporated herein by reference. Background Art

[0002] Brain microvascular endothelial cells (BMECs), one of the constituent cells of the blood-brain barrier (BBB), inhibit the nonspecific entry of substances into the brain parenchyma through strong intercellular adhesion and the expression of efflux transporters. In drug development, this strong barrier function hinders the transfer of candidate drugs to the brain parenchyma (nerve) side, so drug development is sometimes terminated. Therefore, it is expected that a screening model capable of evaluating pharmacokinetics in the human BBB will induce the differentiation of pluripotent stem cells into brain capillary endothelial cells (iBMECs) (for example, Patent Document 1).

[0003] Prior art literature

[0004] Patent Literature

[0005] Patent Document 1: International Publication No. 2019 / 208736 Summary of the invention

[0006] Technical problem that the invention aims to solve

[0007] In Patent Document 1, when inducing human induced pluripotent stem cells (induced pluripotent stem cells: iPS cells) to differentiate into iBMECs, a culture dish coated with Matrigel is used for culture. However, Matrigel has the property of solidifying when the temperature rises, and since the coating requires complicated operations, it is difficult to maintain reproducibility. In addition, since Matrigel is manufactured from mouse granulomas, the differences in the manufacturing companies and manufacturing batches of Matrigel will cause the differentiation efficiency of iBMECs to vary. Therefore, the inventors conducted in-depth research and completed a technology that can provide a stable supply of iBMECs.

[0008] Technical solutions to the problem

[0009] The present invention has been made to solve the above-mentioned problems, and can be implemented as the following aspects.

[0010] (1) According to one embodiment of the present invention, a coating agent is provided for inducing differentiation from pluripotent stem cells into brain capillary endothelial-like cells. The coating agent of this embodiment comprises at least one of a laminin 221 fragment and an N-terminal vitronectin. According to the coating agent of this embodiment, a decrease in reproducibility when inducing differentiation of pluripotent stem cells into brain capillary endothelial-like cells can be suppressed, and further, fluctuations in differentiation efficiency can be suppressed, thereby stably supplying brain capillary endothelial-like cells.

[0011] (2) In the coating agent of the above aspect, the content of the component in the coating agent may be 0.01 nmol / L or more and 10 mmol / L or less. According to the coating agent of this aspect, a decrease in differentiation efficiency can be further suppressed.

[0012] (3) According to another aspect of the present invention, a differentiation induction kit is provided. The differentiation induction kit of this aspect comprises the above-mentioned coating agent and cells. According to the differentiation induction kit of this aspect, pluripotent stem cells can be easily induced to differentiate into brain capillary endothelial-like cells.

[0013] (4) The present invention can also be achieved by use as a coating agent for inducing differentiation of pluripotent stem cells into brain capillary endothelial-like cells, the coating agent for inducing differentiation containing at least one of a laminin 221 fragment and an N-terminal vitronectin.

[0014] (5) According to another embodiment of the present invention, a culture dish is provided, which includes a coating layer coated with a coating agent for inducing differentiation from pluripotent stem cells to brain capillary endothelial-like cells. In the culture dish of this embodiment, the coating agent contains at least one of the laminin 221 fragment and N-terminal vitronectin. According to the culture dish of this embodiment, the reduction in reproducibility when inducing differentiation of pluripotent stem cells to brain capillary endothelial-like cells can be suppressed, and the variation in differentiation efficiency can be suppressed, so that brain capillary endothelial-like cells can be stably supplied.

[0015] (6) In the culture dish of the above-mentioned method, the coating layer may be 2 The coating area contains 1 ng or more and 1 mg or less of the component. According to the coating agent of this embodiment, the reduction in differentiation efficiency can be further suppressed.

[0016] (7) According to another embodiment of the present invention, a method for producing brain capillary endothelial-like cells by inducing differentiation of pluripotent stem cells is provided. The method for producing brain capillary endothelial-like cells of this embodiment includes a step of culturing the pluripotent stem cells using at least one component of the laminin 221 fragment and N-terminal vitronectin. According to the method for producing brain capillary endothelial-like cells of this embodiment, it is possible to suppress the reduction in reproducibility when inducing differentiation of pluripotent stem cells into brain capillary endothelial-like cells, and further, it is possible to suppress the variation in differentiation efficiency, thereby being able to stably supply brain capillary endothelial-like cells.

[0017] (8) In the method for producing brain capillary endothelial-like cells according to the above aspect, the pluripotent stem cells may be induced pluripotent stem cells.

[0018] (9) In the method for producing brain capillary endothelial-like cells according to the above aspect, the induced pluripotent stem cells may be human induced pluripotent stem cells.

[0019] (10) According to another aspect of the present invention, there is provided a method for evaluating the blood-brain barrier permeability of a test substance, wherein the method comprises evaluating the permeability of a test substance using a cell layer of brain capillary endothelial-like cells obtained by the method for producing brain capillary endothelial-like cells according to the above aspect.

[0020] (11) The method for evaluating the blood-brain barrier permeability of the test substance of the above embodiment may include the following steps (i) to (iii).

[0021] (i) a step of preparing the cell layer;

[0022] (ii) a step of bringing the test substance into contact with the cell layer;

[0023] (iii) a step of evaluating the permeability of the test substance by quantifying the amount of the test substance that has passed through the cell layer.

[0024] (12) According to another aspect of the present invention, there is provided a method for evaluating the effect of a test substance on the barrier function of the brain-blood barrier, wherein the evaluation is performed using a cell layer of brain capillary endothelial-like cells obtained by the method for producing brain capillary endothelial-like cells according to the above aspect.

[0025] (13) According to another aspect of the present invention, a method for inducing differentiation of pluripotent stem cells into brain capillary endothelial-like cells is provided. The method for inducing differentiation of pluripotent stem cells into brain capillary endothelial-like cells according to this aspect includes the step of culturing the pluripotent stem cells using at least one of the laminin 221 fragment and N-terminal vitronectin. According to the method for inducing differentiation of pluripotent stem cells into brain capillary endothelial-like cells according to this aspect, it is possible to suppress the reduction in reproducibility when inducing differentiation of pluripotent stem cells into brain capillary endothelial-like cells, and further, it is possible to suppress the variation in differentiation efficiency, thereby being able to stably supply brain capillary endothelial-like cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 is a schematic diagram showing the differentiation protocol of human iPS cells into iBMECs.

[0027] Figure 2 It is a graph showing the relative TEER values ​​of iBMECs induced to differentiate on each coating.

[0028] Figure 3 It is a graph showing the time-dependent changes in TEER values ​​in Matrigel-iBMECs and LN221F-iBMECs derived from the 610B1 strain.

[0029] Figure 4 It is a graph showing the time-dependent changes in TEER values ​​in Matrigel-iBMECs and LN221F-iBMECs derived from the 648A1 strain.

[0030] Figure 5 The graph shows the results of the FD4 permeation test of Matrigel-iBMECs and LN221F-iBMECs.

[0031] Figure 6 It is a graph showing the results of the LY permeation test in Matrigel-iBMECs and LN221F-iBMECs.

[0032] Figure 7 The graphs show the analysis results of the expression levels of each gene in Matrigel-iBMECs, LN221F-iBMECs, and hBMECs.

[0033] Figure 8 The images show the results of protein expression analysis by immunostaining in Matrigel-iBMECs and LN221F-iBMECs.

[0034] Fig. 9 The graphs show the results of functional analysis of P-gp in Matrigel-iBMECs and LN221F-iBMECs.

[0035] Fig.10 The graph shows the results of functional analysis of BCRP in Matrigel-iBMECs and LN221F-iBMECs. DETAILED DESCRIPTION

[0036] The present invention relates to a coating agent for inducing pluripotent stem cells to differentiate into brain capillary endothelial cells. Brain capillary endothelial cells (hereinafter, also referred to as "BMECs") are the main cells constituting the blood-brain barrier (hereinafter, also referred to as "BBB"). The BBB has a structure in which BMECs are surrounded and covered by pericytes and / or astrocytes. According to the present invention, cells similar to BMECs, i.e., brain capillary endothelial cells (hereinafter, also referred to as "iBMECs") showing BMECs characteristics can be obtained. The iBMECs obtained by the method of the present invention are useful for constructing a BBB model, for example, can be used for evaluating the intracerebral migration (blood-brain barrier permeability) of a substance to be tested (typically a drug).

[0037] "Pluripotent stem cells" refer to cells that have both the ability to differentiate into all cells that constitute an organism (differentiation pluripotency) and the ability to produce daughter cells with the same differentiation potential as themselves through cell division (self-replication ability). Differentiation pluripotency can be evaluated by transplanting the cells of the evaluation object into nude mice and testing whether teratomas containing cells of each of the three germ layers (ectoderm, mesoderm, and endoderm) are formed.

[0038] As pluripotent stem cells, there can be listed: embryonic stem cells (ES cells), embryonic germ cells (EG cells), induced pluripotent stem cells (iPS cells), etc., but as long as they are cells with both differentiation pluripotency and self-replication ability, they are not limited to this. ES cells or iPS cells are preferably used. iPS cells are more preferably used. Pluripotent stem cells are preferably cells of mammals (for example, primates such as humans or chimpanzees, rodents such as mice or rats, etc.), and human cells are particularly preferred. Therefore, in the most preferred embodiment of the present invention, human iPS cells are used as pluripotent stem cells.

[0039] ES cells can be established, for example, by culturing early preimplantation embryos, inner cell masses constituting the early embryos, single blastomeres, and the like (Manipulating the Mouse Embryo A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1994); Thomson, JA et al., Science, 282, 1145-1147 (1998)). As early embryos, those prepared by nuclear transplantation of somatic cell nuclei can be used (Wilmut et al. (Nature, 385, 810 (1997)), Cibelli et al. (Science, 280, 1256 (1998)), Iritani et al. (Protein Nuclease, 44, 892 (1999)), Baguisi et al. (Nature Biotechnology, 17, 456 (1999)), Wakayama et al. (Nature, 394, 369 (1998); Nature Genetics, 22, 127 (1999); Proc. Natl. Acad. Sci. USA, 96, 14984 (1999)), Rideout III et al. (Nature Genetics, 24, 109 (2000)), Tachibana et al. (Human Embryonic Stem Cells Derived by Somatic Cell Nuclear Transplantation). Transfer, Cell (2013) in press). As early embryos, parthenogenetic embryos can be used (Kim et al. (Science, 315, 482-486 (2007)), Nakajima et al. (Stem Cells, 25, 983-985 (2007)), Kim et al. (Cell Stem Cell, 1, 346-352 (2007)), Revazova et al. (Cloning Stem Cells, 9, 432-449 (2007)), Revazova et al. (Cloning Stem Cells, 10, 11-24 (2008)).In addition to the above papers, for the preparation of ES cells, reference may be made to Strelchenko N., et al. Reprod Biomed Online. 9: 623-629, 2004; Klimanskaya I., et al. Nature 444: 481-485, 2006; Chung Y., et al. Cell Stem Cell 2: 113-117, 2008; Zhang X., et al Stem Cells 24: 2669-2676, 2006; Wassarman, PM et al. Methods in Enzymology, Vol. 365, 2003, etc. In addition, fused ES cells obtained by cell fusion of ES cells and somatic cells are also included in the embryonic stem cells of the present invention.

[0040] ES cells can be obtained from depository institutions or commercially available. For example, human ES cells can be obtained from the Institute of Regenerative Medicine, Kyoto University (e.g., KhES-1, KhES-2, and KhES-3), WiCell Research Institute, ESI BIO, etc. In addition, ES cells can be established by culturing primordial germ cells in the presence of LIF, bFGF, and SCF (Matsui et al., Cell, 70, 841-847 (1992), Shamblott et al., Proc. Natl. Acad. Sci. USA, 95 (23), 13726-13731 (1998), Turnpenny et al., Stem Cells, 21 (5), 598-609, (2003)).

[0041] iPS cells are cells with pluripotency (multi-differentiation ability) and proliferation ability produced by reprogramming somatic cells by introducing reprogramming factors, etc. iPS cells show properties similar to ES cells. The somatic cells used in the production of iPS cells are not particularly limited, and can be differentiated somatic cells or undifferentiated stem cells. In addition, the source is not particularly limited either, and it is preferred to use somatic cells of mammals (for example, primates such as humans or chimpanzees, rodents such as mice or rats), and it is particularly preferred to use human somatic cells. iPS cells can be produced by various methods reported so far. In addition, it is of course also conceivable to apply iPS cell production methods developed in the future.

[0042] The most basic method for producing iPS cells is to use viruses to introduce four transcription factors, Oct3 / 4, Sox2, Klf4, and c-Myc, into cells (Takahashi K, Yamanaka S: Cell 126 (4), 663-676, 2006; Takahashi, K, et al: Cell 131 (5), 861-72, 2007). For human iPS cells, it has been reported that they were established by introducing four factors, Oct4, Sox2, Lin28, and Nonog (Yu J, et al: Science 318 (5858), 1917-1920, 2007). There are also reports on the establishment of iPS cells using three factors other than c-Myc (Nakagawa M, et al: Nat. Biotechnol. 26 (1), 101-106, 2008), two factors Oct3 / 4 and Klf4 (Kim JB, et al: Nature 454 (7204), 646-650, 2008), or only Oct3 / 4 (Kim JB, et al: Cell 136 (3), 411-419, 2009). In addition, there are also reports on the method of introducing a protein that is an expression product of a gene into cells (Zhou H, Wu S, Joo JY, et al: Cell Stem Cell 4, 381-384, 2009; Kim D, Kim CH, Moon JI, et al: Cell Stem Cell 4, 472-476, 2009). On the other hand, it has also been reported that the use of BIX-01294, an inhibitor of histone methyltransferase G9a, valproic acid (VPA) or BayK8644, an inhibitor of histone deacetylase, can improve production efficiency and reduce the factors that need to be introduced (Huangfu D, et al: Nat. Biotechnol. 26 (7), 795-797, 2008; Huangfu D, et al: Nat. Biotechnol. 26 (11), 1269-1275, 2008; Silva J, et al: PLoS. Biol. 6 (10), e 253, 2008).Gene introduction methods have also been studied. In addition to retroviruses, lentiviruses (Yu J, et al: Science 318 (5858), 1917-1920, 2007), adenoviruses (Stadtfeld M, et al: Science 322 (5903), 945-949, 2008), plasmids (Okita K, et al: Science 322 (5903), 949-953, 2008), and transposon vectors (Woltjen K, Michael IP, Mohseni P, et al: Nature 458, 766-770, 2009; Kaji K, Norrby K, Pac a A, et al: Nature 458, 771-775, 2009; Yusa K, Rad R, Takeda J, et al: Nat Methods 6, 363-369, 2009), or episomal vectors (Yu J, Hu K, Smuga-Otto K, Tian S, et al: Science 324, 797-801, 2009) for gene introduction.

[0043] For cells that have been transformed into iPS cells, i.e., reprogrammed, the expression of pluripotent stem cell markers (undifferentiation markers) such as Fbxo15, Nanog, Oct / 4, Fgf-4, Esg-1, and Cript can be selected as indicators, and the selected cells are recovered as iPS cells.

[0044] iPS cells can be provided by, for example, Kyoto University or the RIKEN Bio Resource Center.

[0045] In this specification, "inducing differentiation" means causing cells to differentiate along a specific cell lineage. In the present invention, when inducing pluripotent stem cells to differentiate into brain capillary endothelial-like cells (iBMECs), a coating agent containing at least one of laminin 221 fragment (hereinafter, also referred to as "LN221F") and N-terminal vitronectin (hereinafter, also referred to as "VTN-N") is used. The details of the coating agent are described below.

[0046] <Coating agent>

[0047] In general, cells are cultured on a culture surface coated with basement membrane components, adhesion molecules, etc., in order to improve cell survival rate, proliferation rate, promote differentiation induction, cell selection, etc. Matrigel, which has been used as a coating agent, has laminin 111 as a main component and contains type IV collagen, heparan sulfate proteoglycan, entactin / nilogen, and various reproductive factors.

[0048] Laminin is a heterotrimeric molecule composed of three subunit chains, namely, an α chain, a β chain, and a γ chain. Five types of α chains are known, namely, α1 to α5, three types of β chains are known, namely, β1 to β3, and three types of γ chains are known, namely, γ1 to γ3. Known laminin reference sequence RNAs include: NM_000426, NM_001079823 (Subunit alpha2), NM_002291 (Subunit beta1), NM_002292 (Subunit beta2), NM_000228 (Subunit beta3), NM_001318046, NM_001318047, NM_001318048, NM_007356 (Subunit beta4), NM_002293 (Subunit gamma 1), NM_005562, NM_018891 (Subunit gamma 2).

[0049] It is known that laminin 221 is a laminin molecule comprising subunit chains of α2 chain, β2 chain, and γ1 chain, and is present in large quantities in the heart.

[0050] In the present specification, "laminin 221 fragment (LN221F)" refers to a fragment (E8 fragment) in laminin 221 that corresponds to the integrin binding site. In addition, the "laminin 221 fragment (LN221F)" in the present specification also includes proteins with high homology to LN221F. In the present specification, "proteins with high homology to LN221F" refer to proteins that contain an amino acid sequence that is more than 80% identical to the amino acid sequence of LN221F in the amino acid sequence constituting the protein. That is, "proteins with high homology to LN221F" also include proteins with longer amino acid sequences than LN221F. From the viewpoint of improving the barrier function, the homology of proteins with high homology to LN221F is preferably 80% or more, more preferably 90% or more, and even more preferably 95% or more. It should be noted that, in general, the molecular weight of the laminin 221 fragment (LN221F) is about 150 kDa to 170 kDa. In this specification, it is assumed that the molecular weight of the laminin 221 fragment (LN221F) is 150 kDa.

[0051] In the present specification, "N-terminal vitronectin (VTN-N)" refers to a protein in which the N-terminus of vitronectin is deleted and contains an RGD sequence. In addition, the "N-terminal vitronectin (VTN-N)" in the present specification also includes proteins with high homology to VTN-N. In the present specification, "proteins with high homology to VTN-N" refer to proteins that contain an amino acid sequence that is more than 70% consistent with the amino acid sequence of VTN-N in the amino acid sequence constituting the protein, or proteins that contain an RGD sequence in the amino acid sequence. "Proteins with high homology to VTN-N" also include proteins whose amino acid sequences are longer than the amino acid sequence of VTN-N. From the viewpoint of improving the barrier function, the homology of proteins with high homology to VTN-N is preferably 80% or more, more preferably 90% or more, and further preferably 95% or more. As a reference sequence RNA for vitronectin, NM_000638 is known, and as a reference sequence protein for vitronectin, NNP_000629 is known. It should be noted that, in this specification, the molecular weight of N-terminal vitronectin (VTN-N) is assumed to be 47.6 kDa.

[0052] The coating agent of the present invention may contain only one of LN221F and VTN-N, or may contain both LN221F and VTN-N. That is, the coating agent of the present invention contains at least one component of LN221F and VTN-N. The coating agent of the present invention preferably contains LN221F. It should be noted that the coating agent of the present invention may also remove the matrix glue. The coating agent may contain the components in an amount of 0.01 nmol / L or more and 10 mmol / L or less. The content of the above-mentioned components in the coating agent is preferably 0.1 nmol / L or more, more preferably 1 nmol / L or more. The content of the above-mentioned components in the coating agent is preferably 1 mmol / L or less, more preferably 0.1 mmol / L or less. By making the coating agent contain the above-mentioned components of 0.01 nmol / L or more, the differentiation efficiency can be improved. In addition, by containing the above-mentioned components of 1 mmol / L or less in the coating agent, the increase in the cost required for differentiation induction can be suppressed.

[0053] The coating agent containing the above-mentioned components can be diluted with a culture medium, etc., and injected into a culture dish or a transwell insert, etc., and allowed to stand, thereby obtaining a culture dish or the like with a coating formed thereon. Hereinafter, forming a coating is also referred to as "coating". The above-mentioned components are applied to the area of ​​the culture dish, i.e., per 1 cm of the coating. 2 The content of the above components is preferably 1 ng or more and 1 mg or less per 1 cm 2The coating area is preferably 10 ng or more, more preferably 0.1 μg or more. In addition, the content of the above components is preferably 10 ng or more per 1 cm 2 The coating area is 0.1 mg or less, more preferably 10 μg or less. 2 The coating area contains 1ng or more of the above ingredients, which can further inhibit the decrease in differentiation efficiency. 2 When the amount of the above-mentioned component contained in the application area is 1 mg or less, an increase in the cost required for differentiation induction can be suppressed.

[0054] <Differentiation Induction Kit>

[0055] In order to manufacture iBMECs, the coating agent can also be provided in the form of a kit combined with cells. That is, according to another embodiment of the present invention, a differentiation induction kit having the coating agent and cells is provided. As cells in the kit, pluripotent stem cells as described above or intermediate cells in the differentiation process of pluripotent stem cells can be used. Such pluripotent stem cells are preferably ES cells or iPS cells, and more preferably iPS cells. In addition, as such pluripotent stem cells, cells of mammals (such as primates such as humans or chimpanzees, rodents such as mice or rats, etc.) are preferably used, and human cells are more preferably used. As intermediate cells in the differentiation process, endothelial progenitor cells are preferably used. That is, the cells in the kit are particularly preferably endothelial progenitor cells differentiated and induced from human iPS cells. In addition, the state of the cells in the kit can be, for example, a state stored at 37°C or a state of frozen storage, etc. From the viewpoint of transportation and handling, the cells in the kit are preferably frozen cells. The user of the kit inoculates the cells for culture after applying the coating agent to a culture dish, or inoculates the coating agent and cells to a culture dish, etc. to culture the cells, so that the cells can be easily induced to differentiate into iBMECs. During cultivation, in addition to the coating agent and cells contained in the kit, other materials can be used in combination, and subculture can be appropriately performed. In addition, as a culture dish, for example, a culture dish of any form such as a petri dish or a cell culture plate with multiple holes can be used.

[0056] Since LN221F and VTN-N do not have the property of solidifying due to temperature rise like Matrigel, they are easier to handle than Matrigel, and since the coating operation is simple, the decrease in reproducibility in differentiation induction can be suppressed. In addition, LN221F and VTN-N are composed of a single component and have little difference between batches, so the fluctuation of the differentiation efficiency of iBMECs caused by differences in manufacturing companies and manufacturing batches can be suppressed. Therefore, according to the present invention, iBMECs can be stably supplied.

[0057] <Method for producing iBMECs by inducing differentiation of pluripotent stem cells>

[0058] In the present invention, the method for producing iBMECs by inducing differentiation of pluripotent stem cells includes a step of culturing pluripotent stem cells using at least one of LN221F and VTN-N. The step may also be a step of inoculating pluripotent stem cells in a culture dish or the like coated with at least one of LN221F and VTN-N during passage, and culturing them using a culture medium.

[0059] As a culture medium used for differentiation induction, for example, a basic culture medium such as DMEM Ham's F-12 (DMEM / F12) and Human Endothelial-SFM can be used. From the perspective of cell proliferation rate and maintenance, it is preferred to add serum or serum substitutes (Knockout serum replacement (KSR) etc.) to the culture medium. Serum is not limited to fetal bovine serum, and human serum or sheep serum etc. may also be used. In addition, instead of using ordinary serum, serum derived from plasma (PDS) may be used. The amount of serum or serum substitute added is, for example, 0.1% (v / v) to 10% (v / v). In the culture medium, it is preferred to add fibroblast growth factor (FGF) 2 such as human FGF2 (for example, human recombinant FGF2), and the added concentration of FGF2 may be, for example, 1ng / mL to 500ng / mL.

[0060] The culture period for differentiation induction may be, for example, 6 to 30 days, preferably 8 to 12 days. By setting the culture period as above, it is possible to suppress the deterioration of the differentiation induction efficiency into iBMECs and to suppress the occurrence of unintended differentiation (differentiation into other cells).

[0061] Subculture can also be performed in the middle of differentiation induction. For example, a part of the cells can be selected and transferred to another culture container when they are fused or not fused, and culture can be continued. When recovering cells, in order to inhibit cell death, ROCK inhibitors (Rho-associated coiled-coilforming kinase / Rho binding kinase) such as Y-27632 can also be used to pre-treat the cells. In addition, in order to improve the selection effect of cells, cells can also be inoculated on a culture surface coated with fibronectin and collagen IV in the middle of differentiation induction.

[0062] Other culture conditions (culture temperature, etc.) can be any conditions commonly used in the culture of animal cells. For example, the cells can be cultured at 37°C and 5% CO2. In addition, the method of culturing cells two-dimensionally using a culture dish or the like is not limited, and three-dimensional culture can also be implemented, using a three-dimensional culture plate or the like coated with the coating of the coating agent. In addition, the coating agent is not limited to being pre-coated on a culture vessel such as a culture dish, and the coating agent and the cell inoculation can also be used simultaneously.

[0063] By the above-mentioned differentiation induction method, iBMECs can be manufactured from pluripotent stem cells. By continuing to culture under culture conditions suitable for the maintenance and proliferation of iBMECs, a monolayer (cell layer) of iBMECs is formed. According to the method of the present invention, a cell layer with excellent barrier function can be obtained. The characteristics of the barrier function of the cell layer obtained by the method of the present invention can be imparted by strong tight junctions and maintaining long-term tight junctions.

[0064] Here, it is generally known that the transendothelial electrical resistance (TEER value), which is an indicator of tight junction, is 1000 to 2000 Ω×cm for BMECs in rats. 2 As a model of human BBB, it is also preferred to have 1000Ω×cm 2 Above TEER value.

[0065] According to the method for producing iBMECs of this embodiment, a TEER value of 1000 Ω×cm 2 In addition, the cell layer can maintain more than 1000Ω×cm for a long time. 2 TEER value, for example, maintained for more than 9 days.

[0066] The barrier function of the cell layer obtained by the method of the present invention can also be further imparted by having important or characteristic drug transporters (such as BCRP, P-gp, GLUT1) in BMEC. In addition, the expression of important or characteristic tight junction markers (such as Claudin5, Occludin, ZO-1) in BMEC can be used as an indicator to determine or evaluate the function of iBMECs.

[0067] In the later stage of differentiation induction, by culturing on a semipermeable membrane (porous membrane), a cell layer of iBMECs can be formed on the semipermeable membrane. This mode is particularly effective in the case where the cell layer of iBMECs obtained by the manufacturing method of the present invention is used for various assays. For example, a culture container (e.g., Transwell (registered trademark) provided by Corning) with a culture insert (having a culture surface including a semipermeable membrane) can be used to culture cells in the insert to form a cell layer.

[0068] Other embodiments of the present invention relate to the use of iBMECs made by differentiation induction using the above method. As described above, according to the present invention, a cell layer composed of iBMECs can be obtained, and the cell layer can be used in a BBB model. For example, detection using this cell layer is useful for evaluating the BBB permeability of a pharmaceutical or candidate pharmaceutical substance to be tested. Therefore, a method for evaluating the BBB permeability of a substance to be tested using a cell layer of iBMECs obtained by the manufacturing method of the present invention (hereinafter also referred to as "the BBB permeability evaluation method of the present invention") can be provided. In the BBB permeability evaluation method of the present invention, the following steps (i) to (iii) are performed.

[0069] (i) Step of preparing a cell layer of iBMECs obtained by the production method of the present invention

[0070] (ii) A step of bringing the test substance into contact with the cell layer

[0071] (iii) a step of evaluating the permeability of the test substance by quantifying the test substance that has passed through the cell layer.

[0072] In step (i), prepare the cell layer of iBMECs obtained by the manufacture method of the present invention.It should be noted that, in addition to the cell layer of iBMECs, other cells (pericytes, astrocytes, etc.) can also be used.For example, the cell layer of iBMECs can be formed in the culture plug-in (forming a cell layer on the bottom upper surface of the culture plug-in) using a culture container equipped with a culture plug-in, and culture pericytes (pericytes adhesion co-culture system) under the state of adhering to the bottom back of the culture plug-in, or utilize the area between the culture plug-in and the hole to cultivate pericytes (pericytes non-adhesion co-culture system), or cultivate pericytes under the state of adhering to the bottom back of the culture plug-in and utilize the area between the culture plug-in and the hole to cultivate astrocytes (pericytes adhesion / astrocyte non-adhesion co-culture system), or cultivate astrocytes (astrocyte adhesion co-culture system) under the state of adhering to the bottom back of the culture plug-in.

[0073] The "contact" in step (ii) is typically performed by adding the test substance to the culture medium. The timing of adding the test substance is not particularly limited. Therefore, after starting the culture with a culture medium that does not contain the test substance, the test substance can be added at a certain time point, or the culture can be started with a culture medium that previously contains the test substance.

[0074] Typically, a substance of a pharmaceutical or candidate pharmaceutical is used as a test substance. However, the test substance is not particularly limited, and organic compounds or inorganic compounds of various molecular sizes can be used as the test substance. As examples of organic compounds, there can be exemplified: nucleic acids, peptides, proteins, lipids (simple lipids, complex lipids (phosphodiester, sphingolipids, glycoglycerides, cerebrosides, etc.), prostaglandins, isoprenoids, terpenes, steroids, polyphenols, catechins, vitamins (B1, B2, B3, B5, B6, B7, B9, B12, C, A, D, E, etc.). Plant extracts, cell extracts, culture supernatants, etc. can also be used as test substances. By adding two or more test substances at the same time, interactions, synergistic effects, etc. between the test substances can be studied. The test substance can be a natural or synthetic substance. If a synthetic substance is used, an effective detection system can be constructed using, for example, a combinatorial synthesis technique.

[0075] The contact time of the test substance can be set arbitrarily. The contact period is, for example, 10 minutes to 3 days, preferably 1 hour to 1 day.

[0076] In step (iii), the substance to be tested that passes through the cell layer is quantified. For example, in the case of using a culture container with a culture plug-in such as Transwell (registered trademark), the substance to be tested that has passed through the culture plug-in, that is, the substance to be tested that has moved to the upper container (culture plug-in) or the lower container (hole) via the cell layer is quantified using a determination method corresponding to the substance to be tested. As a determination method, examples include: mass spectrometry, liquid chromatography, immunological techniques (for example, fluorescent immunoassay (FIA method: Fluorescent Immunoassay), enzyme immunoassay (EIA method: Enzyme Immunoassay)) and other determination methods. According to the quantitative results (the amount of the substance to be tested after passing through the cell layer) and the amount of the substance to be tested used (typically the amount added to the culture medium), the membrane permeability of the substance to be tested is evaluated. In addition to membrane permeability, the absorption (absorbability) of the cell layer, the effect on the cell layer (for example, the effect on the barrier function), the expression of transport proteins (such as BCRP or P-gp) or the effect on the function, etc. can also be evaluated. Usually, since absorbability and permeability have a bilateral relationship, they can be evaluated by the same method as permeability. The influence on barrier function can be evaluated by the determination of TEER value, permeation test using non-absorbent markers, etc. In addition, the influence on transporter expression can be evaluated by immunological techniques, Western blotting, flow cytometry, etc., for example, by activity tests using substrates to evaluate the influence on the function.

[0077] As can be seen from the above description, by using the cell layer of iBMECs, it is also possible to evaluate the impact of the test substance on BBB function (such as the improvement, reduction, and damage of BBB function). Therefore, in the present invention, as other uses of the cell layer of iBMECs manufactured by the manufacturing method of the present invention, there is also provided an evaluation method with BBB function as a target or object, i.e., a method for evaluating the impact of the test substance on BBB function. This evaluation method is useful, for example, as a means of exploring substances such as substances that enhance (improve) barrier function, substances that protect barrier function, substances that regulate barrier function, etc. In addition, it can also be used to evaluate the toxicity to BBB. In this evaluation method, similarly to the above-mentioned BBB permeability evaluation method, the process of preparing the cell layer and the process of contacting the test substance with the cell layer are performed, and then, the impact of the cell layer on barrier function is evaluated. The technology for evaluating the impact on barrier function is as described above.

[0078] [Example]

[0079] The present invention is described in more detail below by way of examples, but the present invention is not limited to the following examples. It should be noted that, in the following description, unless otherwise specified, "%" represents volume % (volume / volume%), and "w / v%" represents weight / volume % (weight / volume%). In addition, the materials used in the examples were obtained from the companies shown in Table 1.

[0080] [Table 1]

[0081] Table 1

[0082]

[0083] 1. Materials and Methods

[0084] (1) Culture medium

[0085] In the culture of mouse embryonic fibroblasts (MEF) as feeder cells, Dulbecco's modified eagle medium (DMEM) containing 10% fetal bovine serum (FBS), 2mmol / L L-glutamine (L-Glu), 1% non-essential amino acids (NEAA), and 1× penicillin-streptomycin was used. 0.05w / v% trypsin-ethylenediaminetetraacetic acid (EDTA) was used as the detachment solution for MEF, and CELLBANKER1 was used as the storage solution for MEF. In the maintenance culture of human iPS cells, DMEM Ham's F-12 (DMEM / F12) containing 20% ​​KnockOut Serum Replacement (KSR), 0.8% NEAA, 2mmol / L L-Glu, 0.1mmol / L 2-mercaptoethanol (2-MeE), and 5ng / mL fibroblast growth factor (FGF) 2 was used. Dulbecco's phosphate buffered saline (PBS) containing 1 mg / mL collagenase IV, 0.25 w / v% trypsin, 20% KSR, and 1 mmol / L calcium chloride was used as the detachment solution for human iPS cells. Cell Reservoir One was used as the storage solution for human iPS cells.

[0086] (2) Cultivation of human iPS cells

[0087] As human iPS cells, 610B1 strain and 648A1 strain (both obtained from RIKEN) were used. Human iPS cells were seeded on MEFs (6×105 cells / 100 mm dish) and cultured in a CO2 incubator at 37°C under 5% CO2 / 95% air conditions. Human iPS cells were passaged at a split ratio of 1:2 to 1:4 after 3 to 5 days of culture.

[0088] (3) Coating agent

[0089] Matrigel GFR (Growth Factor Reduced), Fibronectin (hereinafter also referred to as "FBN"), N-terminal vitronectin (hereinafter also referred to as "VTN-N"), laminin 221 fragment (hereinafter also referred to as "LN221F"), laminin 411 fragment (hereinafter also referred to as "LN411F"), and laminin 511 fragment (hereinafter also referred to as "LN511F") are used as coating agents at the beginning of differentiation induction. In addition, during the subculture in the middle of differentiation induction, a mixture of fibronectin and type IV collagen is used as a coating agent. In the following description, matrigel GFR is also referred to as "matrigel". It should be noted that the concentration of the coating agent containing the above-mentioned LN221F is 175μg / 0.35mL, and the concentration of the coating agent containing the above-mentioned VTN-N is 0.5mg / mL.

[0090] (4) Coating formation

[0091] The coating was formed using each of the above coating agents. For Matrigel, it was diluted 30-fold with the human iPS cell maintenance medium on ice, injected into the well plate, and allowed to stand at 37°C for more than 30 minutes to form a coating. For FBN, VTN-N, LN221F, LN411F, and LN511F, the concentration was 1 μg / cm 2 The mixtures of fibronectin and type IV collagen were diluted with PBS to 100 μg / mL and 400 μg / mL, respectively, injected into the transwell insert, and left to stand at 37°C for 2 hours to form coatings.

[0092] (5) Differentiation induction of human iPS cells into iBMECs

[0093] Figure 1 Schematic diagram showing the differentiation protocol of human iPS cells into iBMECs. Figure 1As shown, when inducing differentiation of human iPS cells into iBMECs, matrigel and the above-mentioned single basement membrane components were used as coating agents from differentiation day 0 to differentiation day 8 of iBMECs. Differentiation induction was inoculated in a culture dish coated with each of the above-mentioned coating agents during passage, and cultured with StemSure hPSC medium containing 35ng / mL FGF2, starting when the proportion of undifferentiated colonies was about 60-70% (differentiation day 0). After culturing for 6 days in a DMEM / F12-based culture medium containing 20% ​​KSR, 0.8% NEAA, 2mmol / L L-Glu, and 0.1mmol / L 2-MeE (differentiation day 6), the cells were cultured for 2 days in a culture medium containing 10μM all-trans retinoic acid (RA) and 20ng / mL FGF2 added to a HE-SFM-based culture medium containing 1% platelet-poor plasma-derived serum (PDS) and 1× penicillin-streptomycin added to human endothelial-SFM (HE-SFM). Thereafter (differentiation day 8), the cells were stripped with Accutase and 3×10 cells were seeded on a transwell insert or culture dish coated with fibronectin and type IV collagen. 5 cells / well. After culturing in HE-SFM-based culture medium containing 10 μM RA and 20 ng / mL FGF2 for 1 day, (9th day of differentiation), differentiation into iBMECs was induced by culturing in HE-SFM-based culture medium (without RA and FGF2 addition). No culture medium change was performed after the 9th day of differentiation.

[0094] (6) Determination of transendothelial electrical resistance (TEER) value

[0095] The TEER values ​​of iBMECs (differentiation day 10) from 610B1 strain induced and differentiated on matrigel or FBN, VTN-N, LN221F, LN411F, and LN511F were measured. The number of samples was set to 3, and the relative TEER values ​​of iBMECs induced and differentiated on FBN, VTN-N, LN221F, LN411F, and LN511F were obtained based on the TEER values ​​of iBMECs induced and differentiated on matrigel (hereinafter, also referred to as "matrigel-iBMECs"). In addition, for those from 610B1 strain and 648A1 strain, the TEER values ​​of matrigel-iBMECs and iBMECs induced and differentiated on LN221F (hereinafter, also referred to as "LN221F-iBMECs") were measured, respectively, from the first day after inoculation (differentiation day 9) to the tenth day after inoculation (differentiation day 18). The number of samples was set to 6, and the change in TEER value over time was determined. TEER value was measured using Millicell ERS-2 (Choustick type) according to the instruction manual. The volume of the culture medium was 300 μL on the apical side and 800 μL on the basal side.

[0096] (7) Permeation test of fluorescein isothiocyanate-dextran 4kDa (FD4) and lucifer yellow (LY)

[0097] For those from the 610B1 strain and the 648A1 strain, the permeation test of FD4 and LY was performed on Matrigel-iBMECs and LN221F-iBMECs, respectively. The number of samples was 6. On the tenth day of differentiation, the culture medium was replaced with transport buffer (HBSS containing 10mM HEPES solution) and cultured at 37°C for 20 minutes. Transport buffer containing 1mg / mL FD4 or 300μM LY was added to the apical side. After incubation at 37°C for 60 minutes, 100μL of solution was recovered from the basal side. The volume of transport buffer was 300μL on the apical side and 800μL on the basal side. The fluorescence intensity of FD4 or LY was measured using a Synergy HTX multimode microplate reader and analyzed using Gen5 data analysis software.

[0098] (8) RNA extraction

[0099] The extraction was performed according to the manual attached to the Agencourt (registered trademark) RNAdvance Tissue Kit.

[0100] (9) Reverse transcription reaction

[0101] Complementary DNA (cDNA) synthesis was performed using ReverTra Ace (registered trademark) qPCR RT Master Mix according to the attached manual.

[0102] (10) RT-qPCR

[0103] RT-q PCR was used to analyze the gene expression levels in Matrigel-iBMECs and LN221F-iBMECs (tenth day of differentiation) from the 610B1 strain and primary BMECs from humans (hereinafter also referred to as "hBMECs"). The number of samples for Matrigel-iBMECs and LN221F-iBMECs was set to 3, and the number of samples for hBMECs was set to 1. RT-qPCR was performed using the KAPA SYBR FastqPCR Kit with cDNA as a template according to the attached manual. The primer sequences used in RT-q PCR are shown in Table 2. The obtained results were corrected using HPRT1 as an internal reference. The expression level of mRNA in Matrigel-iBMECs was used as a benchmark, and the relative expression levels of mRNA in LN221F-iBMECs and hBMECs were calculated. It should be noted that as RT-q The primers used in PCR are shown in sequence number 1 for the forward primer of CDH5, sequence number 2 for the reverse primer of CDH5, sequence number 3 for the forward primer of MDR1, sequence number 4 for the reverse primer of MDR1, sequence number 5 for the forward primer of BCRP, sequence number 6 for the reverse primer of BCRP, sequence number 7 for the forward primer of GLUT1, sequence number 8 for the reverse primer of GLUT1, and sequence number 9 for the reverse primer of GLUT1. The sequence of the forward primer of occludin is shown in sequence number 9, the sequence of the reverse primer of occludin is shown in sequence number 10, the sequence of the forward primer of ZO-1 is shown in sequence number 11, the sequence of the reverse primer of ZO-1 is shown in sequence number 12, the sequence of the forward primer of LAT1 is shown in sequence number 13, the sequence of the reverse primer of LAT1 is shown in sequence number 14, the sequence of the forward primer of HPRT1 is shown in sequence number 15, and the sequence of the reverse primer of HPRT1 is shown in sequence number 16.

[0104] [Table 2]

[0105] Table 2

[0106]

[0107] (11) Immunostaining

[0108] Immunostaining analysis was performed for Matrigel-iBMECs and LN221F-iBMECs (differentiation day 10) from the 610B1 strain to analyze the protein expression and local presence of BMEC markers. The antibodies used in immunostaining are shown in Table 3. For Zonula occludens-1 (ZO-1) and occludin, cells on a 96-well plate were fixed in 4w / v% paraformaldehyde for 15 minutes at room temperature, washed twice with PBS containing glycine, and then permeabilized with PBS containing 0.1w / v% Triton X-100 for 25 minutes at room temperature. Blocking was performed with 5% donkey serum at room temperature for 20 minutes, and then the primary antibody was reacted at room temperature for 2 hours. Washed 3 times with PBS, and then the secondary antibody was reacted at room temperature for 60 minutes at a dilution of 200 times. At this time, 1μg / mL DAPI as a nuclear staining reagent was reacted simultaneously. Then, washed 3 times with PBS and analyzed using the Operetta high-content imaging system. Regarding cadherin 5 (CDH5), claudin 5, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP), cells on a 96-well plate were washed three times with D-PBS (-) containing 0.1w / v% BSA, fixed in 4w / v% paraformaldehyde for 15 minutes, washed again three times with PBS containing 0.1w / v% BSA, and then permeabilized with PBS containing 0.1w / v% Triton X-100 for 5 minutes. Next, the cells were washed three times with PBS containing 0.1w / v% BSA, and then reacted with primary antibodies at 4°C overnight. Then, the cells were washed three times with PBS containing 0.1w / v% BSA, and the secondary antibodies (Anti-Rabbit, Anti-Mouse) were diluted 200 times and reacted at room temperature for 60 minutes. Then, the cells were washed three times with PBS containing 0.1w / v% BSA, and 1μg / mL DAPI was reacted for 5 minutes. Then, the cells were reacted in 4 w / v% paraformaldehyde for 5 minutes, washed three times with PBS, and analyzed using the Operetta high-content imaging system.

[0109] [Table 3]

[0110] Table 3

[0111]

[0112] (12) Functional analysis of P-gp and BCRP

[0113] For Matrigel-iBMECs and LN221F-iBMECs (differentiation day 10) from the 610B1 strain, a substrate uptake test was performed to perform functional analysis of P-gp and BCRP as transport proteins. Rhodamine 123 and hoechst 33342 were used as substrates. The culture medium was removed and the cells on the 96-well plate were cultured in transport buffer at 37°C for 15 minutes. It should be noted that the number of samples was 6. In the presence or absence of 10 μM cyclosporin A (CsA) as a P-gp inhibitor or 20 μM Ko 143 as a BCRP inhibitor, incubated at 37°C for 60 minutes in a transport buffer containing 10 μM rhodamine 123 or 10 μM hoechst 33342. Then, the cells were washed three times with PBS, lysed with PBS containing 5 w / v% Triton X-100, and the fluorescence intensity of rhodamine 123 and hoechst 33342 was measured using a Synergy HTX multimode microplate reader and analyzed using Gen5 data analysis software.

[0114] 2. Results and Investigation

[0115] (1) Relative TEER value based on Matrigel-iBMECs

[0116] Figure 2 is a graph showing the relative TEER values ​​of iBMECs induced and differentiated on each coating. Figure 2 In the figure, the vertical axis represents the relative TEER value when the TEER value of Matrigel-iBMECs is set as 1.0, and the horizontal axis represents the type of iBMECs. Figure 2 The results showed that iBMECs differentiated on LN221F and VTN-N showed higher TEER values ​​than iBMECs differentiated on Matrigel. In particular, LN221F-iBMECs showed a TEER value about 2 times higher than Matrigel-iBMECs. Therefore, it can be said that iBMECs differentiated on LN221F or VTN-N have a higher barrier function than iBMECs differentiated on Matrigel.

[0117] (2) Changes in TEER value over time

[0118] Figure 3 It is a graph showing the time-dependent changes in TEER values ​​in Matrigel-iBMECs and LN221F-iBMECs derived from the 610B1 strain. Figure 4 This is a graph showing the time-dependent changes in TEER values ​​in Matrigel-iBMECs and LN221F-iBMECs derived from the 648A1 strain. Figure 3 and Figure 4 The vertical axis represents the TEER value (Ω×cm 2 ), the horizontal axis represents the number of days after inoculation. Figure 3 and Figure 4 The results shown show that even when either the 610B1 strain or the 648A1 strain is used as human iPS cells, LN221F-iBMECs show a higher TEER value than Matrigel-iBMECs for a long time. That is, it can be said that iBMECs induced to differentiate on LN221F have a long-term high barrier function compared to iBMECs induced to differentiate on Matrigel. In addition, it can be seen that when either the 610B1 strain or the 648A1 strain is used as human iPS cells, LN221F-iBMECs also show a TEER value of 1000Ω×cm for a long time. 2 The above TEER values ​​are useful as a model of human BBB.

[0119] (3) Permeability test

[0120] Figure 5 The graph shows the results of the FD4 permeation test in Matrigel-iBMECs and LN221F-iBMECs. Figure 6 Graph showing the results of a LY permeation test in Matrigel-iBMECs and LN221F-iBMECs. Figure 5 and Figure 6 The vertical axis represents the transmittance coefficient (10 -6 cm / sec), and the horizontal axis represents the types of iBMECs. Figure 5 and Figure 6 The results shown show that even when either the 610B1 strain or the 648A1 strain is used as human iPS cells, and when either FD4 or LY, which is an index of permeation based on the paracellular pathway, is used as a permeation target, LN221F-iBMECs show a lower permeability coefficient than Matrigel-iBMECs. It is known that a high TEER value is shown for a long time. That is, it can be said that iBMECs induced to differentiate on LN221F have a higher barrier function than iBMECs induced to differentiate on Matrigel.

[0121] The results of the TEER value measurement and the permeation test suggest that LN221F-iBMECs have a higher barrier function than Matrigel-iBMECs. Therefore, it is known that LN221F-iBMECs are useful as a model of human BBB.

[0122] (4) Analysis of gene expression based on RT-q PCR

[0123] Figure 7 : is a graph showing the analysis results of the expression level of each gene in Matrigel-iBMECs, LN221F-iBMECs, and hBMECs. Figure 7 In the figure, the vertical axis represents the relative expression level of mRNA when the expression level of mRNA of each gene in Matrigel-iBMECs is set as 1.0, and the horizontal axis represents the type of iBMECs or BMECs. Figure 7 The results shown show that even when any one of CDH5, MDR1, BCRP, ZO-1, Occludin, GLUT1, and LAT1 was used as a BMEC marker, LN221F-iBMECs showed an expression level that was almost equivalent to that of Matrigel-iBMECs.

[0124] (5) Confirmation test of protein expression by immunostaining

[0125] Figure 8 The images show the results of protein expression analysis by immunostaining in Matrigel-iBMECs and LN221F-iBMECs. Figure 8 In the figure, a 50 μm scale bar is shown together with the image obtained by immunofluorescence staining. Figure 8 The results shown show that even when any of CDH5, P-gp, BCRP, ZO-1, Occludin, and Claudin 5 was used as a BMEC marker, LN221F-iBMECs showed protein expression levels and localization that were almost equivalent to those of Matrigel-iBMECs.

[0126] The results of the gene expression and protein expression confirmation tests showed that LN221F-iBMECs have properties as BMECs, similar to Matrigel-iBMECs, and therefore, it was found that LN221F-iBMECs are useful as a model of human BBB.

[0127] (6) Substrate absorption test

[0128] Fig. 9 The graphs show the results of functional analysis of P-gp in Matrigel-iBMECs and LN221F-iBMECs. Fig.10 This figure shows the results of functional analysis of BCRP in Matrigel-iBMECs and LN221F-iBMECs. Fig. 9 and Fig.10 In the graph, the vertical axis represents the relative substrate accumulation amount when the substrate accumulation amount in the absence of an inhibitor of the efflux transporter is set as 1.0, and the horizontal axis represents the presence or absence of an inhibitor of the efflux transporter. Fig. 9 and Fig.10The results shown confirmed that, like Matrigel-iBMECs, in the presence of an inhibitor of the efflux transporter, the amount of substrate accumulation in LN221F-iBMECs increased compared to the absence of the inhibitor. Therefore, it is known that LN221F-iBMECs have the functions of P-gp and BCRP like Matrigel-iBMECs.

[0129] 3. Summary

[0130] The above results show that by using LN221F or VTN-N as a coating agent for inducing differentiation of iBMECs, iBMECs having a higher barrier function can be prepared compared to the case of using Matrigel.

[0131] Industrial Applicability

[0132] According to the present invention, iBMECs that can construct a BBB model with high barrier function can be stably differentiated and induced from pluripotent stem cells. Therefore, iBMECs can be stably supplied, which can help establish a supply system for iBMECs for pharmaceutical companies or research institutions. In addition, the BBB model constructed using the present invention can be used in, for example, an evaluation system for the effectiveness / safety of pharmaceuticals.

[0133] The present invention is not limited by the embodiments and examples of the invention described above. Various modifications are also included in the present invention without departing from the description of the claims and within the scope that can be easily thought of by those skilled in the art. The contents of papers, patent publications, patent documents, etc. explicitly mentioned in this specification are cited by citing their entire contents.

[0134] Sequence number 1: Description of artificial sequence: CDH5 forward primer

[0135] Sequence number 2: Description of artificial sequence: CDH5 reverse primer

[0136] Sequence number 3: Description of artificial sequence: MDR1 forward primer

[0137] Sequence number 4: Description of artificial sequence: MDR1 reverse primer

[0138] Sequence number 5: Description of artificial sequence: BCRP forward primer

[0139] SEQ ID NO. 6: Description of artificial sequence: BCRP reverse primer

[0140] Sequence No. 7: Description of artificial sequence: GLUT1 forward primer

[0141] Sequence No. 8: Description of artificial sequence: GLUT1 reverse primer

[0142] SEQ ID NO. 9: Description of artificial sequence: Occludin forward primer

[0143] SEQ ID NO. 10: Description of artificial sequence: Occludin reverse primer

[0144] SEQ ID NO. 11: Description of artificial sequence: ZO-1 forward primer

[0145] SEQ ID NO. 12: Description of artificial sequence: ZO-1 reverse primer

[0146] SEQ ID NO. 13: Description of artificial sequence: LAT1 forward primer

[0147] SEQ ID NO. 14: Description of artificial sequence: LAT1 reverse primer

[0148] SEQ ID NO. 15: Description of artificial sequence: HPRT1 forward primer

[0149] SEQ ID NO. 16: Description of artificial sequence: HPRT1 reverse primer

Claims

1. A method for producing brain capillary endothelial-like cells, characterized in that: The production method produces brain capillary endothelial-like cells by inducing differentiation of pluripotent stem cells. The production method includes the step of culturing the pluripotent stem cells using laminin 221E8 as a coating agent.

2. The method for producing brain capillary endothelial-like cells according to claim 1, wherein: The pluripotent stem cells are induced pluripotent stem cells.

3. The method for producing brain capillary endothelial-like cells according to claim 2, wherein: The induced pluripotent stem cells are human induced pluripotent stem cells.